HEADLINES:

NEW GLOBAL INDUSTRY COALITION AND LEADING DIGITAL HEALTH PLATFORM AIMS TO DRAMATICALLY INCREASE ACCESS FOR ALL PATIENT POPULATIONS IN CLINICAL TRIALS AND RESEARCH

Parsippany, NJ – July 16, 2021
Medocity joins a historic alliance of over one hundred life sciences and healthcare organizations that seeks to accelerate the broad adoption of patient-focused, decentralized clinical trials and research. The “Decentralized Trials & Research Alliance (DTRA),” which launched December, 2020, is uniting industry stakeholders, including healthcare companies, regulators, patient groups and research organizations with a singular mission to make clinical trial participation widely accessible by advancing policies, research practices and new technologies in decentralized clinical research.

“We are delighted to be a member of DTRA to help shape the innovative approach to clinical trial design and conduct,” said Amy Apostoleris, Global Head of Digital Clinical Trials Solutions at Medocity. “Decentralized trials provide access to diverse groups of patients and physicians, which in turn bring therapies that better reflect all people to the market rapidly. By advancing patient engagement and improving lives through a patient centered digital health platform we can make the clinical trial process more patient-focused, increase trial efficiency and encourage use of technologies. This is in strong alignment with our company mission to utilize digital health technology to make a difference by improving all lives and providing hope to their loved ones.”

“We are extremely gratified to welcome Medocity to the ‘Decentralized Trials & Research Alliance,’ said Amir Kalali, MD, founder of several collaborative life science communities, and co-Chair of DTRA. “By advancing decentralized research we can make the clinical trial process more patient-focused, increase trial efficiency and encourage use of technologies. We are excited by Medocity’s commitment to embracing decentralized trials and to changing the culture that has been the rate limiter to innovation.”

Experts estimate that COVID-19 may set back non-pandemic clinical trials by several years due to prospective patients’ inability or reluctance to schedule visits at physical research locations. Decentralized approaches to conducting research facilitate participation by a more diverse patient population and could ease COVID-19-imposed difficulties for both patients and clinical investigators. Inclusion of representative patient populations in clinical trials by race, age and geographic location has long been an operational challenge. COVID-19 has amplified the disparities and inclusion biases that have become hurdles for potential trial participants.

“Now is the time to share ideas and insights that will chart the future course of clinical trials, accelerating drug development and saving lives – and by taking part in the DTRA, Medocity is demonstrating its leadership to drive change,” said Craig Lipset, DTRA co-Chair, clinical innovation advisor, and a pioneer in decentralized trials. “We have a responsibility to advance the health of people with unmet medical needs, and by convening stakeholders from pharma companies, regulators, technology leaders and patient communities, we can remove remaining barriers to adoption and impact patients today.”

Medocity joins with its peer DTRA Member organizations to provide expertise to identify and address gaps and needs and advance best practices through effective education and communication. Medocity urges other organizations interested in taking part to visit DTRA.org

ABOUT MEDOCITY:

Medocity is a leading digital health solutions provider that supports decentralized clinical research and RWE generation through its unique, patient-focused end-to-end digital health enterprise platform serving pharmaceutical companies across clinical development and market commercialization. We collaborate with clinical development teams, CROs, sites and academic institutions from study concept to close, conducting decentralized clinical trials, including HEOR and RWE studies. Medocity engages patients throughout their disease journey to improve health outcomes; and enables the capture of continuous patient-centered data for trial and real-world clinical insights. Accessible in real time on any device, our technology seamlessly integrates with EMR data, claims data, lab data, EDC, CTMS and IRT systems, plus hundreds of connected sensors, sources and systems. Medocity’s unique AI/ML algorithm can match patients to rare disease clinical studies and also encourages inclusion and diversity. Our platform increases retention and compliance, accelerates study timelines, improves outcomes, and lowers healthcare costs. Any device. Any disease. Anywhere. Any time.

ABOUT DTRA:
The Decentralized Trials & Research Alliance (DTRA) was convened to enable collaboration of stakeholders to accelerate the adoption of patient-focused, decentralized clinical trials and research within life sciences and healthcare through education and research. It works to make research participation accessible to everyone, enabled by the consistent, widespread adoption of appropriate decentralized research methods. Follow DTRA on Twitter and LinkedIn for more information.

#     #     #

Medocity Media Contact:

Terence Maytin
‭(973) 671-5155
tmaytin@medocity.com

DTRA Media Contacts:

Glenn Silver
Lazar – Finn Partners
glenn.silver@finnpartners.com
973-818-8198

For Non-media Inquiries:
DTRA Secretariat
secretariat@dtra.org
619-209-7371